Please login to the form below

Not currently logged in

MHRA signs new cooperation deal

The Medicines and Healthcare products Regulatory Agency has signed a new deal with the UK's governing body for pharmacists.

The Medicines and Healthcare products Regulatory Agency (MHRA) has signed a new deal with the UK's governing body for pharmacists.

The MHRA announced on March 5 that it has agreed to a closer working relationship and cooperation with the Royal Pharmaceutical Society of Great Britain.

Pledging to strengthen working relationships and achieve core objectives, the respective CEOs of the two organisations signed a memorandum of understanding.

Professor Kent Woods, CEO at the MHRA, said: "It is a positive step forwards to better information sharing between the two organisations."

"I feel this will enable a greater interaction between the Society and the MHRA, both working to a common goal of safeguarding public health."

By ensuring regular communication, the MHRA and the Society aim to build upon areas of joint cooperation and create an open atmosphere for information sharing.

While maintaining clear boundaries, the two regulatory bodies hope to organise joint training for inspectors and to conduct joint investigations if the circumstances of a case require expertise from both organisations.

Jeremy Holmes, chief executive and chief registrar of the Royal Pharmaceutical Society, said: "Together, the MHRA and the Society will work towards making Britain the safest place to take medicines."

"This partnership will improve working procedures and will help both organisations benefit from each other's knowledge and expertise."

6th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...